Comment on: Clinical Characteristics, Diagnosis, and Treatments for COVID-19
- PMID: 38809378
- DOI: 10.1007/s11596-024-2897-8
Comment on: Clinical Characteristics, Diagnosis, and Treatments for COVID-19
Similar articles
-
Monoclonal Antibody and Oral Antiviral Treatment of SARS-CoV-2 Infection in US Nursing Homes.JAMA. 2023 Aug 8;330(6):561-563. doi: 10.1001/jama.2023.12945. JAMA. 2023. PMID: 37450293 Free PMC article.
-
The COVID-19 pandemic: a stress test for clinical epidemiology.Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):28-29. doi: 10.19191/EP20.5-6.S2.100. Epidemiol Prev. 2020. PMID: 33412791 English. No abstract available.
-
Update to living systematic review on drug treatments for covid-19.BMJ. 2021 Mar 31;372:n858. doi: 10.1136/bmj.n858. BMJ. 2021. PMID: 33789885 No abstract available.
-
Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.Curr Mol Med. 2021;21(7):562-572. doi: 10.2174/1566524020666201203170230. Curr Mol Med. 2021. PMID: 33272178 Review.
-
Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.Eur Heart J. 2021 Mar 1;42(9):882-883. doi: 10.1093/eurheartj/ehab043. Eur Heart J. 2021. PMID: 33569601 Free PMC article. Review. No abstract available.
References
-
- Lalonde CS, Zhuang TZ, Aldredge AA, et al. Abstract 444: COVID-IRIS: Immune reconstitution after G-CSF administration for neutropenia during acute COVID-19 infection. Cancer Res, 2022,82(12_Supplement):444 - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical